12/8/2004 Australia Amanda Hodge The Australian (www.theaustralian.news.com) IT'S 7pm, the Christmas carols at the office party are on a loop and you have four hours to drink the boss broke at the complimentary bar. In a country where alcohol is so intrinsic to celebrations that jolly is a euphemism for drunk, Christmas is the season for sanctioned binge drinking. During the next month, millions of litres of beer, wine and bubbles will be consumed in an orgy of hedonism. And in Australia this indulgence isn't limited to the festive season. It's a year-round event. Binge drinking is one of our most intractable and expensive health issues, costing $7.6 billion a year in lost productivity, absenteeism, injuries, death and disease. On any weekend, 75 per cent of the patients in emergency wards will have alcohol-related complaints. A 2003 survey by the National Centre for Education and Training on Addiction found most alcohol-related harm comes not from alcohol-dependant people but from low to moderate consumers who binge. "Eighty per cent of alcohol consumed in Australia is consumed at risky levels," says emeritus professor and chairman of the Alcohol Education and Rehabilitation Foundation Ian Webster. "That's accepted as normal and it ought not to be." Drinking patterns among younger Australians is of particular concern, especially given recent reports of binge drinking by children as young as 12. Recent surveys found that among 14 to 17-year-olds, 64 per cent of boys and 69 per cent of girls were drinkers. Between one-quarter to one-third of [...]

12/7/2004 Ora Israel et al. Journal of Nuclear Medicine Vol. 45 No. 12 2045-2051 Rising serum tumor markers may be associated with negative imaging in the presence of cancer. CT and 18F-FDG PET may yield incongruent results in the assessment of tumor recurrence. The present study evaluates the incremental role of 18F-FDG PET/CT for the diagnosis and management of cancer patients with increasing levels of tumor markers as the sole indicator of potential recurrence after initial successful treatment. Methods: Thirty-six cancer patients with increasing levels of tumor markers during follow-up and negative CT underwent 18F-FDG PET/CT, which showed 111 sites of increased tracer uptake. PET/CT was compared with PET results on a site-based analysis for characterization of 18F-FDG foci and on a patient-based analysis for diagnosis of recurrence. The clinical impact of PET/CT on further patient management was evaluated. Results: Thirty patients (83%) had recurrence in 85 malignant sites (77%). For the site-based analysis, PET had a sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 96%, 50%, 85%, 85%, and 82%, respectively, as compared with the performance indices of PET/CT of 100%, 89%, 97%, 97%, and 100%, respectively. There was a statistically significant difference between the specificity (P < 0.05) and accuracy (P < 0.001) of PET and PET/CT for precise characterization of suspected lesions. For the patient-based analysis, PET had a sensitivity, specificity, and accuracy of 93%, 50%, and 86%, respectively, as compared with PET/CT with values of 93%, 67%, and 89%, respectively (P = not [...]

12/4/2004 Amy Dockser Marcus The Wall St. Journal Cancer screening is getting easier, with new tests available — and many more in the works — that can detect the disease even in tiny amounts, when it still is in its earliest stages. Some of the new tests use just a small amount of saliva or urine to search for molecular changes in cells that indicate the cancer process is under way. Others use high-speed computers to identify genetic signatures of cancer in the blood. Advanced imaging machines are becoming more widely available that enable doctors to spot cancers smaller than the size of a period at the end of a sentence. But the debate over who should take advantage of the newer screens, and even some of the older ones, is intense. While cells may look abnormal under a microscope, they may never grow into something that harms the patient. “We are beginning to understand that there are some cancers that are better for people not to know about,” says H. Gilbert Welch, a senior research associate with the Department of Veterans Affairs in White River Junction, Vt. At the same time, some cancers are so aggressive or unpredictable that knowing about them early may be of little use. Barnett Kramer, associate director for disease prevention at the National Institutes of Health, says finding a cancer early is sometimes like being tied down to a railroad track and being given a pair of binoculars: “You can see the train coming [...]

12/3/2004 New Haven, CT Press Release Yahoo! Finance(biz.yahoo.com) CuraGen Corporation announced today it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for CG53135, a novel protein therapeutic being developed for the prevention and treatment of oral mucositis (OM). Under the FDA granted designation CG53135 will be investigated for the prevention of OM in patients receiving hematopoietic stem cell transplantation (HSCT) following myeloablative chemotherapy with or without total body irradiation (TBI). "Oral mucositis is a serious and debilitating side effect resulting from the chemotherapy and radiation used in the treatment of cancer. Patients receiving a bone marrow transplant who develop oral mucositis may experience significant pain which can lead to an inability to eat or drink, and have an increased risk of developing a life-threatening infection," stated Mary E. Taylor, Vice President of Regulatory Affairs at CuraGen. "As we continue to advance CG53135 through Phase II, we are pleased to have received fast track status and look forward to working closely with the FDA to develop this therapeutic." CG53135 is an investigational protein discovered by CuraGen that promotes both epithelial and mesenchymal cell proliferation. Data from the recently completed Phase I program evaluating CG53135 for the prevention of OM in patients receiving high dose chemotherapy followed by hematopoietic stem cell transplantation will be presented on Saturday, December 4th at the 46th Annual Meeting of the American Society of Hematology in San Diego, CA. CG53135 is currently in a Phase II program to evaluate its safety and [...]

12/3/2004 Nikki V Katz Womens Issues (womensissues.about.com) Statistics on women smokers, the side-effects and a new campaign specifically targetting women. According to the U.S. Surgeon's General Report on Women and Smoking (issued in 03/01) and recent research studies, it has been found that: -178,000 women die of tobacco-caused disease each year -Since 1987, lung cancer has been the leading cancer-killer among women -Since 1980, approximately 3 million U.S. women have died prematurely from smoking-related diseases, as well as cigarette-caused burns. -Heart disease is the number one killer of women, and smoking accounts for 20% of deaths from heart disease -Women suffer gender specific risks from tobacco, including harm to their reproductive organs and complications during pregnancy -From 1991 to 1999, smoking increased 30% among high school girls For many decades, tobacco companies have attempted to lure new female customers by associating smoking with a woman's independence and sophistication. Advertising campaigns such as Virginia Slims' "You've Come A Long Way, Baby" and the new "It's A Woman Thing" have presented smoking as signs of freedom and individuality. In the 1970s, women were targeted with advertising for so-called "low tar" and "light" brands, with implied claims of reduced risk that the tobacco companies knew to be false. Current Anti-Smoking Campaign: In June, 2002, the American Legacy Foundation (the national, independent public health foundation established by the 1988 tobacco settlement) is releasing a print campaign in women's magazines. The women featured in this campaign are real women battling tobacco-related illnesses like emphysema, lung [...]

12/3/2004 New York, NY Angela Stewart The Star Ledger With cancer survival rates significantly improved for both adults and children, the American Society of Clinical Oncology said yesterday it is creating a national task force to address the physical, emotional and practical needs of this growing population. There are 9.8 million cancer survivors in the United States, compared to 3 million in 1971. They now represent 3.5 percent of the population. But follow-up care often is lacking, cancer survivors reported in a recent poll, noting that their non-medical needs are going unmet. In an effort to close the gap, the oncology society has formed a Survivorship Task Force that will seek to improve the long- term care of cancer survivors, in large part by better training the oncologists who treat them. "Even if we have the knowledge, if we don't communicate it to patients, it is of no value," said David Johnson, society president, during an annual educational event the organization sponsored at the Millennium Broadway Hotel in midtown. The event featured experts from the National Cancer Institute, some of the leading cancer centers and support groups in the country to discuss issues such as long-term effects of cancer therapy, risk of recurrence and second cancers and psycho-social issues. For many years, medical professionals focused on little other than treatment when it came to cancer patients, admitted Julia Rowland, director of the Office of Cancer Survivorship at the NCI. She said there is a growing movement today, however, to continue [...]

12/2/2004 Adam S. Jacobson, MD; Mark L. Urken, MD, FACS ACS Surgery: Principles & Practice Sources of False Negative PET Scans Using FDG A range of physiologic tracers has been developed for positron emission tomography (PET), with the glucose analogue F-18 fluorodeoxyglucose (FDG) the most commonly used. FDG has a half-life of 110 minutes. Once given to the patient, FDG is taken up by glucose transporters and is phosphorylated by hexokinase to become FDG-6-phosphate (FDG-6-P). Further metabolism of FDG-6-P is blocked by the presence of an extra hydroxyl moiety, which allows FDG-6-P to accumulate in the cell and serve as a marker for glucose metabolism and utilization. Because FDG is nonspecifically accumulated in glycolytically active cells, it demarcates areas of inflammation as well as neoplastic tissue; this can lead to a false positive scan. Muscular activity during the scan can also lead to areas of increased uptake in nonneoplastic tissue. Furthermore, healing bone, foreign-body granulomas, and paranasal sinus inflammation can produce false positive results. False negative scans occur when tumor deposits are very small (3 to 4 mm or less in diameter). Thus, micrometastases are not reliably detected using an FDG-PET image. Furthermore, a false negative scan can occur if the PET is performed too soon after radiation therapy.

12/2/2004 Laurie Barclay, MD Medscape (www.medscape.com) Four cycles of neoadjuvant chemotherapy is a promising approach for treating patients with inoperable advanced head and neck squamous cell carcinoma (HNSCC), according to follow-up data from a 10-year randomized trial published in the Nov. 17 issue of the Journal of the National Cancer Institute. "Chemoradiotherapy is the standard treatment for locally advanced HNSCC; the standard treatment for patients with operable HNSCC is surgery followed by postoperative radiotherapy, with or without adjuvant chemotherapy," write Pier Luigi Zorat, from Ospedale Ca' Foncello in Treviso, Italy, and colleagues. "Although neoadjuvant chemotherapy has a proven role in organ preservation and statistically significantly reduces the incidence of distant metastases, especially in laryngeal and hypopharyngeal cancers, its efficacy in prolonging overall survival has not yet been demonstrated." The investigators compared induction chemotherapy with cisplatin and 5-fluorouracil followed by locoregional treatment (surgery and radiotherapy or radiotherapy alone) with locoregional treatment alone in patients with HNSCC. In this multicenter trial, 237 patients with nonmetastatic stage III or IV HNSCC were randomized to receive four cycles of neoadjuvant chemotherapy followed by locoregional treatment (group A) or locoregional treatment alone (group B). In group A, overall survival at five and 10 years was 23% (95% confidence interval [CI], 15.3% - 30.9%) and 19% (95% CI, 11.6% - 26.4%). In group B, the corresponding survival rates were 16% (95% CI, 9.6% - 23.4%) and 9% (95% CI, 3.5% - 14.7%; P = .13). For operable patients, there was no difference between group A and [...]

12/2/2004 Jukka H. Meurman; Mariano Sanz; Sok-Ja Janket3 Crit Rev Oral Biol Med 15(6):403-413 (2004) During the last two decades, there has been an increasing interest in the impact of oral health on atherosclerosis and subsequent cardiovascular disease (CVD). The advent of the inflammation paradigm in coronary pathogenesis stimulated research in chronic infections caused by a variety of micro-organisms—such as Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus—as well as dental pathogens, since these chronic infections are thought to be involved in the etiopathogenesis of CVD by releasing cytokines and other pro-inflammatory mediators (e.g., C-reactive protein [CRP], tumor necrosis factor [TNF-]) that may initiate a cascade of biochemical reactions and cause endothelial damage and facilitate cholesterol plaque attachment. Yet, due to the multi-factorial nature of dental infection and CVD, confirming a causal association is difficult, and the published results are conflicting. The main deficit in the majority of these studies has been the inadequate control of numerous confounding factors, leading to an overestimation and the imprecise measurement of the predictor or overadjustment of the confounding variables, resulting in underestimation of the risks. A meta-analysis of prospective and retrospective follow-up studies has shown that periodontal disease may increase the risk of CVD by approximately 20% (95% confidence interval [CI], 1.08–1.32). Similarly, the reported risk ratio between periodontal disease and stroke is even stronger, varying from 2.85 (CI 1.78–4.56) to 1.74 (CI 1.08–2.81). The association between peripheral vascular disease and oral health parameters has been explored in only two studies, and the resultant relative [...]

12/2/2004 Pathak KA et al. Nature Clinical Practice Oncology (2004) 1, 60-61 Damage to the submandibular salivary glands is an important side effect of head and neck radiation therapy. The resulting xerostomia causes problems with chewing, swallowing and changes to the oral microbial flora, adversely affecting the patient's quality of life. Pathak and colleagues have described a technique for protecting the contralateral submandibular salivary gland from radiation by transferring it to the submental space prior to treatment. This approach has been used previously in patients undergoing neck dissection as part of primary treatment. The new study, however, deals with those patients not requiring neck dissection. A total of 22 patients with oropharyngeal or hypopharyngeal tumors underwent contralateral submandibular salivary gland transfer (SMSGT) as an upfront, day care procedure. The incision was small, extending from the tip of the greater horn of hyoid to the midpoint of the submental space. The operating time was approximately 20 minutes. All patients went on to receive radical radiotherapy within 2 weeks of the procedure. Unstimulated pre-radiation and post-radiation salivary output was measured by cannulating the submandibular ducts. The mean salivary output of the transferred gland was 73% after radiotherapy, compared with only 27% for the untransferred, ipsilateral gland. The authors conclude that SMSGT maintained adequate salivary gland function in these patients and that the procedure was simple, safe and cost effective